Overall, these data indicate that IRF4 sustains the oncogenic properties of STAT3 in T-cell lymphomas, and that its inhibition represents an alternative avenue to interfere with STAT3 signaling and offers promising therapeutic opportunities to treat and prevent drug resistance in ALCL patients. The gene discussed is STAT3; the disease is anaplastic large cell lymphoma.